About 800 reports

Other Lymphoma Treatment Drugs

  • Lymphoma
  • China
  • Prescription Drug Sales
  • Industrial Production

“Follicular lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...

  • Lymphoma
  • World

Abstract: - Global Lymphoma Therapeutics Market to Reach $23.6 Billion by 2027 - Amid the COVID-19 crisis, the global market for Lymphoma Therapeutics estimated at US$14.9 Billion in the year 2020, is projected to reach a revised size of US$23.6 Billion by 2027, growing at aCAGR of 6.8% over the period 2020-2027....

  • Lymphoma
  • World
  • China
  • United States

‘Severe Toxicities in Lymphoma - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Severe Toxicities in Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Severe Toxicities in Lymphoma Understanding Lymphoma...

  • Lymphoma
  • Germany
  • Spain
  • France
  • Italy
  • United Kingdom
  • United States
  • World
  • Japan

‘Follicular Lymphoma - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Follicular Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered • The United...

  • Lymphoma
  • United States
  • Japan
  • Spain
  • France
  • Germany
  • Italy
  • United Kingdom

‘Marginal Zone Lymphoma—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the MZL, historical and forecasted epidemiology as well as the MZL trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. Marginal Zone Lymphoma Disease Understanding Marginal...

  • Lymphoma
  • United States
  • Spain
  • France
  • United Kingdom
  • Japan
  • Germany
  • Italy

BY TYPE OF LYMPHOMA

  • Lymphoma
  • APAC
  • Europe
  • North America
  • Africa
  • Health Expenditure
  • Stem Cell Transplantation

"Indolent Lymphoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Indolent Lymphoma. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed...

  • Lymphoma
  • World
  • United States
  • Health Expenditure

Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021 Summary Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) (Oncology) - Drugs in Development, 2021 provides an overview...

  • Lymphoma
  • World

Burkitt Lymphoma (Oncology) - Drugs in Development, 2021 Summary Burkitt Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Burkitt Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma,...

  • Lymphoma
  • World

Follicular Lymphoma (Oncology) - Drugs in Development, 2021 Summary Follicular Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Follicular Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Follicular...

  • Lymphoma
  • World

Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 Summary Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for...

  • Lymphoma
  • Therapy
  • Research And Development
  • World

‘Severe Toxicities in Lymphoma - Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the Severe Toxicities in Lymphoma, historical and forecasted epidemiology as well as the Severe Toxicities in Lymphoma market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),...

  • Lymphoma
  • United States
  • Germany
  • Spain
  • France
  • Japan
  • Italy
  • United Kingdom
  • Health Expenditure
  • Medical Technology Density

Global Mantle Cell Lymphoma Therapeutics Market: About this market Mantle cell lymphoma therapeutics are available in combination therapy and monotherapy. This mantle cell lymphoma therapeutics market analysis considers sales from the combination therapy and monotherapy segments. Our analysis also considers the sales...

  • Therapy
  • Lymphoma
  • World

Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 Summary Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Lymphoblastic Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under...

  • Lymphoma
  • Therapy
  • Research And Development
  • World

Mantle Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Mantle Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Mantle Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mantle...

  • Lymphoma
  • World

Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase or MALT1 or EC 3.4.22.) - Drugs in Development, 2021 Summary Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT Lymphoma Associated Translocation or Paracaspase...

  • Lymphoma
  • World

‘Marginal Zone Lymphoma-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the MZL, historical and forecasted epidemiology as well as the MZL market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. The Marginal Zone Lymphoma market report...

  • Lymphoma
  • Therapy
  • United States
  • Spain
  • Japan
  • United Kingdom
  • France
  • Germany
  • Italy

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) (Oncology) - Drugs in Development, 2021 Summary Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) (Oncology) - Drugs in Development, 2021 provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline...

  • Cancer
  • Lymphoma
  • World

Natural Killer Cell Lymphomas (Oncology) - Drugs in Development, 2021 Summary Natural Killer Cell Lymphomas (Oncology) - Drugs in Development, 2021 provides an overview of the Natural Killer Cell Lymphomas pipeline landscape. The report provides comprehensive information on the therapeutics...

  • Cell Therapy
  • Lymphoma
  • World

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2021-2025 The analyst has been monitoring the anaplastic lymphoma kinase (ALK) inhibitors market and it is poised to grow by $ 3.43 billion during 2021-2025, progressing at a CAGR of almost 22% during the forecast period. Our report on anaplastic lymphoma kinase...

  • Lymphoma
  • World

Anaplastic Large Cell Lymphoma (ALCL) (Oncology) - Drugs in Development, 2021 Summary Anaplastic Large Cell Lymphoma (ALCL) (Oncology) - Drugs in Development, 2021 provides an overview of the Anaplastic Large Cell Lymphoma (ALCL) pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

Primary Mediastinal B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Primary Mediastinal B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

Marginal Zone B-cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Marginal Zone B-cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Marginal Zone B-cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics...

  • Lymphoma
  • World

B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 Summary B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 provides in depth analysis on B Cell Lymphoma 2 (Bcl 2) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage...

  • Lymphoma
  • World

Splenic Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Splenic Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Splenic Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

Nodal Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 Summary Nodal Marginal Zone B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Nodal Marginal Zone B-Cell Lymphoma pipeline landscape. The report provides comprehensive information...

  • Lymphoma
  • World

B Cell Lymphoma/Leukemia 11A (B Cell CLL/Lymphoma 11A or COUP TF Interacting Protein 1 or Ecotropic Viral Integration Site 9 Protein Homolog or Zinc Finger Protein 856 or BCL11A) - Drugs in Development, 2021 Summary B Cell Lymphoma/Leukemia 11A (B Cell CLL/Lymphoma 11A or COUP TF Interacting Protein...

  • Lymphoma
  • Immunotherapy
  • World

ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 Summary ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis on ALK Tyrosine Kinase Receptor...

  • Lymphoma
  • Research And Development
  • Drug Development
  • World

Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 Summary Cells Expressing ALK Tyrosine Kinase Receptor (Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis...

  • Lymphoma
  • Research And Development
  • Drug Development
  • World